Telesis Bio Conversione FCF

Cosa fa Telesis Bio? Telesis Bio Inc, trading under the ticker TBIO with ISIN US1920032000, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 212 employees and completed its initial public offering on June 18, 2021. Telesis Bio Inc's website is https://codexdna.com/. The company focuses on research and development of genomic tools for biomedical and industrial applications. Its synthetic biology solutions aim to address challenges in the multi-step process of constructing DNA and mRNA, overcoming limitations that hinder scalable production. The BioXp system, an end-to-end automated workstation, is a key product offering. The company provides BioXp systems, including the BioXp 3250 model, along with BioXp kits for generating synthetic DNA and mRNA, and benchtop reagents designed to support automated synthetic biology workflows. Additional products include eight BioXp kits, three benchtop reagent kits, and various synthetic biology solutions such as 14 SARS-CoV-2 full-length genomes and RNA controls. The company has deployed approximately 200 BioXp systems globally. Telesis Bio Inc is engaged in developing tools that enhance the efficiency and scalability of genomic research and applications. Telesis Bio è una delle aziende più popolari su Eulerpool.com.